Figure 1.
Flow sheet of questions on patients with human epidermal growth factor receptor 2 (HER2)-positive, metastatic breast cancers; panels were asked the 1st line treatment to 4th line treatment in sequence with (line) or without (dotted line) consideration of practical issues, showing T-DM 1, if practical, commanded 100% agreement at each sequence.